Synchronous and antecedent malignancies in patients with papillary thyroid carcinoma

Abstract

Objective. This study aimed to evaluate concurrently detected second primary malignancy in the patients who underwent surgery for papillary thyroid carcinoma. Methods. In this study, we retrospectively analyzed the files of the patients who underwent surgery for papillary thyroid carcinoma between 2000-2017. A total number of 601 patients with papillary thyroid carcinoma were evaluated. Among these patients, 48 patients were found to have secondary primary tumors. Preoperative and postoperative laboratory examination findings of the patients were retrospectively recorded. Results. Among 601 patients with papillary thyroid cancer evaluated with respect to radiation exposure, the second primary tumor with breast cancer was found to be the most common tumor. Renal cell carcinoma, malignant melanoma and stomach cancer were found to be more frequent when evaluated regardless of radiation effect. Furthermore, when molecular genetic results were evaluated, BRAF mutation rate was found to be more frequent than in other secondary tumors, especially in patients with renal cell carcinoma. Conclusions. The importance of epidemiological and experimental studies of multiple cancers is obvious. Although it is known that the impact of radiation is considerable among the ones with concurrence of breast cancer and papillary thyroid carcinoma, we suggest that further studies on common molecular genetic characteristics and development of targeted treatment for detected molecules are required in the patients with renal cell carcinoma in whom papillary thyroid carcinoma is diagnosed regardless of radiation effect. 

Keywords

• Papillary thyroid carcinoma,second primary carcinoma,carcinogenesis,renal cell carcinoma

References

1. [1] Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
2. [2] Wynder EL, Mushinski MH, Spivak JC. Tobacco and alcohol consumption in relation to the development of multiple primary cancers. Cancer 1977;40:1872-8.
3. [3] Murray SE, Schneider DF, Bauer PS, Sippel RS, Chen H. Synchronous and antecedent nonthyroidal malignancies in patients with papillary thyroid carcinoma. J Am Coll Surg 2013;216:1174-80.
4. [4] Artac M, Bozcuk H, Ozdogan M, Demiral AN, Sarper A, Samur M, et al. Different clinical features of primary and secondary tumors in patients with multiple malignancies. Tumori 2005;91:317-20.
5. [5] Tachimori Y. Cancer screening in patients with cancer. Jpn J Clin Oncol 2002;32:118-9.
6. [6] Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003;26:79-83.
7. [7] Crocetti E, Arniani S, Buiatti E. Synchronous and metachronous diagnosis of multiple primary cancers. Tumori 1998;84:9-13.
8. [8] Hemminki K, Boffetta P. Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. IARC Sci Publ 2004;157:289-97.

9. [9] Carey TE. Field cancerization: are multiple primary cancers monoclonal or polyclonal? Ann Med 1996;28:183-8.
10. [10] Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
11. [11] Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996;56:2484-7.
12. [12] Dong C, Hemminki K. Multiple primary cancers of the colon, breast and skin (melanoma) as models for polygenic cancers. Int J Cancer 2001;92:883-7.
13. [13] van Westreenen HL, Westerterp M, Jager PL, van Dullemen HM, Sloof GW, Comans EF, et al. Synchronous primary neoplasms detected on 18FFDG PET in staging of patients with esophageal cancer. J Nucl Med 2005;46:1321-5.
14. [14] Kagei K, Hosokawa M, Shirato H, Kusumi T, Shimizu Y, Watanabe A, et al. Efficacy of intense screening and treatment for synchronous second primary cancers in patients with esophageal cancer. Jpn J Clin Oncol 2002; 32:120-127.
15. [15] Palou J, Rodríguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A, et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 2005;174:859-61.
16. [16] Koutsopoulos AV, Dambaki KI, Datseris G, Giannikaki E, Froudarakis M, Stathopoulos E. A novel combination of multiple primary carcinomas: urinary bladder transitional cell carcinoma, prostate adenocarcinoma and small cell lung carcinoma-report of a case and review of the literature. World J Surg Oncol 2005;3:51.
17. [17] Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 2001;92:1-8.
18. [18] Suzuki T, Takahashi H, Yao K, Inagi K, Nakayama M, Makoshi T, et al. Multiple primary malignancies in the head and neck: a clinical review of 121 patients. Acta Otolayngol Suppl 2002;547:88-92.
19. [19] Shikhani AH, Matonoski GM, Jones MM, Kashima HK, Johns ME. Multiple primary malignandes in head and neck cancer. Arch Otolaryngol Head Neck Surg 1986;112:1172-5.
20. [20] Healy MJ, Murphy E, Taub J, Azzari R. Multiple (five) primary malignant lesions. Am J Surg 1970;119:343-47.
21. [21] Balducci L, Beghe C. Cancer and age in the USA. Crit Rev Oncol Hematol 2001;37:137-45.
22. [22] Wynder EL, Mushinsky MH, Spivak JC. Tobacco and alcohol consumption in relation to the development of multiple primary cancers. Cancer 1977;40:1872-928.
23. [23] Li FP, Fraumeni JF. Prospective study of a family cancer syndrome. JAMA 1982;247:2692-4.
24. [24] Bhatia S, Robinson LL, Obertin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334:745-51.
25. [25] Supramaniam R. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. J Epidemiol Community Health 2008;62:375-6.